B. H. Tai et al. / Bioorg. Med. Chem. Lett. 21 (2011) 3462–3466
3465
120
80
40
0
*
*
*
**
**
**
**
**
**
**
**
**
**
**
+ + + -
Comp. 8
+
PDGF-BB (25 ng/mL)
+ + + - + + + - + + + - + + + -
+
+ + + - + + + -
AG1295
Comp. 1
Comp. 2
Comp. 3
Comp. 4 Comp. 5
Comp. 7
Concentration (µM)
Figure 4. Effects of selected compounds on PDGF-BB-induced proliferation in rat aortic VSMCs. AG1295 (1
lM), a PDGF-BB receptor inhibitor, was used as a positive control
of anti-proliferative agents. Data are expressed as Mean SD (n = 4, ⁄P <0.05, ⁄⁄P <0.01 vs stimulus control).
8. Lee, Y. J.; Kyoung, M. M.; Hwang, S. M.; Yoon, J. J.; Lee, S. M.; Seo, K. S.; Kim, J. S.;
Kang, D. G.; Lee, H. S. Am. J. Chin. Med. 2010, 38, 585.
9. Lee, Y. J.; Kim, J. S.; Kang, D. G.; Lee, H. S. Exp. Biol. Med. 2010, 235, 247.
10. Nishimura, H.; Sasaki, H.; Morota, T.; Chin, M.; Mitsuhashi, H. Phytochemistry
1989, 28, 2705.
11. Miyase, T.; Akahori, C.; Kohsaka, H.; Ueno, A. Chem. Pharm. Bull. 1991, 39, 2944.
12. Calis, I.; Zor, M.; Basaran, A. A.; Wright, A. D.; Sticher, O. J. Nat. Prod. 1993, 56,
606.
13. Morikawa, H.; Kasai, R.; Otsuka, H.; Hirata, E.; Shinzato, T.; Aramoto, M.;
Takeda, Y. Chem. Pharm. Bull. 2004, 52, 1086.
14. Calis, I.; Yuruker, A.; Ruegger, H.; Wright, A. D.; Sticher, O. Helv. Chim. Acta
1993, 76, 2563.
15. Yamamoto, A.; Miyase, T.; Ueno, A.; Maeda, T. Chem. Pharm. Bull. 1991, 39,
2764.
16. Pistelli, L.; Bilia, A. R.; Marsili, A.; De-Tommasi, N.; Manunta, A. J. Nat. Prod.
1993, 56, 240.
17. Liu, Z.; Li, D.; Owen, N. L.; Grant, D. M.; Cates, R. G.; Jia, Z. Nat. Prod. Lett. 1995, 6,
157.
18. Fan, C. Q.; Sun, H. F.; Chen, S. N.; Yue, J. M.; Lin, Z. W.; Sun, H. D. Nat. Prod. Lett.
2002, 16, 161.
19. Ebata, N.; Nakajima, K.; Hayashi, K.; Okada, M.; Maruno, M. Phytochemistry
1996, 41, 895.
20. Yamamoto, A.; Miyase, T.; Ueno, A.; Maeda, T. Chem. Pharm. Bull. 1993, 41,
1780.
21. Ding, N.; Yahara, S.; Nohara, T. Chem. Pharm. Bull. 1992, 40, 780.
22. Klimek, B. Phytochemistry 1996, 43, 1281.
most of compounds significantly inhibited VSMCs proliferation at a
concentration of 50 M (Fig. 3). Of these, compounds 1–5, 7 and 8
l
showed the potent inhibitory effects, while compounds 9–14 did
not show inhibitory effects on VSMCs proliferation after treatment
with 25 ng/mL homodimer platelet-derived growth factor beta
polypeptide (PDGF-BB). Compounds 6, 15–20 showed the pattern
of cytotoxic effects. Based on the above results, compounds 1–5,
7 and 8 were then further tested for concentration-dependent ef-
fects on VSMCs (0–50
centration of 50 M (Fig. 4). Compound 1 significantly decreased
cells proliferation at 10, 30 and 50 M, with inhibition of 39.1%,
lM) as they showed no cytotoxicity at con-
l
l
42.0% and 79.6%, respectively. Compounds 7 and 8 showed moder-
ate inhibition by 22.6% and 21.2%, respectively, at a concentration
of 30
compounds showed significantly inhibition effects on the prolifer-
ation of VSMCs at a concentration of 10 M. These results clearly
lM. With the exception of compounds 1 and 3, none of these
l
indicated that the iridoids from B. officinalis have potent inhibitory
effects on rat aortic VSMC proliferation and may be useful for the
treatment of atherosclerosis.
23. Dried flowers of B. officinalis Maxim. (2.0 kg) were extracted with methanol at
room temperature three times. After removal of the solvent under reduced
pressure, the crude extract (94.37 g) was dissolved in 1.0 L of H2O to form a
suspension that was successively partitioned with dichloromethane (CH2Cl2),
ethyl acetate (EtOAc), and n-butanol (BuOH) to give CH2Cl2 (10.77 g), EtOAc
(12.70 g), and BuOH (27.29 g) extracts, respectively. The BuOH extract was
then subjected to column chromatography using SiO2 (70–230 mesh), eluting
with Me2CO/CHCl3/H2O (3:1:0.2, v/v/v) to give five fractions (1a–e). Repeated
silica gel column chromatography of fraction 1a with CH2Cl2/MeOH/H2O
Acknowledgments
We would like to thank the Ministry of Science and Technology,
Vietnam, for financial support in form of the Vietnam-Korea Interna-
tional Collaboration Project (No. 30/823/2007/HD-NDT). This work
was supported partly by Priority Research Centers Program through
the National Research Foundation of Korea (NRF) funded by the Min-
istry of Education, Science and Technology (2009-0093815), Repub-
lic of Korea.
(4.5:1:0.1, v/v/v) and Me2CO/CHCl3/H2O (3.5:1:0.1) to give compounds
3
(13 mg) and 4 (18 mg). Fraction 1b was then subjected to a silica gel column
using an isocratic eluent of CHCl3/Me2CO/MeOH/H2O (3:2:1:0.1, v/v/v/v) and
further by YMC column with MeOH/H2O (1:2, v/v) afford compounds 1(9 mg),
2 (15 mg) and 5 (12 mg). Compounds 15 (14 mg), 16 (12 mg), and 19 (15 mg)
were isolated from fraction 1d using a silica gel column with CH2Cl2/MeOH/
H2O (4:1:0.1, v/v/v), further by YMC column and eluting with Me2CO/H2O (2:1,
v/v). Finally, fraction 1e was chromatographed using a YMC column with
MeOH/H2O (2:3, v/v) to afford five fractions (2a–e). Compounds 17 (90 mg), 18
(30 mg), and 20 (18 mg) were obtained from YMC gel column chromatography
of sub-fractions 2d and 2e. The purity of isolated compounds was more than
97% by high-performance liquid chromatography (HPLC) analysis.
References and notes
1. Piao, M. S.; Kim, M. R.; Lee, D. G.; Park, Y. K.; Hahm, K. S.; Moon, Y. H.; Woo, E. R.
Arch. Pharm. Res. 2003, 26, 453.
2. Guo, H.; Koike, K.; Li, W.; Satou, T.; Guo, D.; Nikaido, T. J. Nat. Prod. 2004, 67, 10.
3. Tai, B. H.; Jung, B. Y.; Cuong, N. M.; Linh, P. T.; Tung, N. H.; Nhiem, N. X.; Huong,
T. T.; Anh, N. T.; Kim, J. A.; Kim, S. K.; Kim, Y. H. Biol. Pharm. Bull. 2009, 32, 1952.
4. Bich, D. H.; Chung, D. Q.; Chuong, B. X.; Dong, N. T.; Dam, D. T.; Hien, P. V.; Lo, V.
N.; Mai, P. D.; Man, P. K.; Nhu, D. T.; Tap, N.; Toan, T. 1st ed., Sci-Techn. Publ.
House: Hanoi, Vietnam, 2004; Vol. II, p 251.
5. Liao, Y. H.; Houghton, P. J.; Hoult, J. R. S. J. Nat. Prod. 1999, 62, 1241.
6. Lee, Y. J.; Kang, D. G.; Kim, J. S.; Lee, H. S. Phytother. Res. 2008, 22, 1655.
7. Lee, Y. J.; Kang, D. G.; Kim, J. S.; Lee, H. S. Exp. Biol. Med. 2008, 233, 694.
24. Compound 1 (2.0 mg) was dissolved in 1.0 N HCl (dioxane/H2O, 1:1, v/v,
1.0 mL) and then heated to 80 °C in a water bath for 3 h. The acidic solution
was neutralized with silver carbonate and the solvent thoroughly driven out
under N2 gas overnight. After extraction with ethyl acetate, the aqueous layer
was concentrated to dryness using N2 gas. The residue was dissolved in 0.1 mL
of dry pyridine, and then L-cysteine methyl ester hydrochloride in pyridine